Company: IXHL
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001213900-25-092837
Chunk: 174

Company: Incannex Healthcare Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 174
---
 drug candidate or license our intellectual property may
fail to protect our intellectual property rights to the same extent as the protection that may be afforded in the United States or Australia.
Some countries in Europe and China have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third
parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these
countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are, or any of
our licensors is, forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position
or commercial advantage may be impaired, and our business and results of operations may be adversely affected.

Some legal principles remain unresolved and there
has not been a consistent policy regarding the breadth or interpretation of claims allowed in patents in the United States, the United
Kingdom, the European Union, Australia or elsewhere. In addition, the specific content of patents and patent applications that are necessary
to support and interpret patent claims is highly uncertain due to the complex nature of the relevant legal, scientific and factual issues.
Changes in either patent laws or in interpretations of patent laws in Australia, the United States, the United Kingdom, the European Union
or elsewhere may diminish the value of our intellectual property or narrow the scope of our patent protection. Even if we are able to
obtain patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with
us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar
or alternative technologies or products in a non-infringing manner and export infringing products to territories where we do not have
patent protection, or to territories where we have patent protection, but where enforcement is not as strong as that in the United States.
These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient
to prevent them from competing. We may also fail to take the required actions or pay the necessary fees to maintain our patents.

Moreover, any of our pending applications may be
subject to a third-party pre-issuance submission of prior art to the USPTO, the European Patent Office (“EPO”), the Intellectual
Property Office, in the United Kingdom, the Australian Patent and Trademark Office and/or any patents issuing thereon may become involved
in opposition, derivation, re